Company intelligence / Profile preview

Hefei TG ImmunoPharma Co., Ltd.

Hefei, Anhui Sheng, Chinaprobiocdmo.com ↗

Ownership: Private
Development stage: Phase 1

Overview

The company has received FDA clearance for clinical trials of TGI-2 (anti-PVRIG therapeutic antibody) and TGI-6 (bispecific antibody). TGI-2 has initiated Phase 1 trials in the United States. TGI-6 has demonstrated superior anti-tumor activity and safety in preclinical studies and is in Phase 1 trials for locally advanced/metastatic solid tumors.

Therapeutic areas: OncologyImmunology
Modalities: Monoclonal antibodiesBispecific antibodiesTrispecific antibodiesNK/T-cell engagersImmunocytokinesBiological products
Industry: Biotech

Drug pipeline

5 assets

NM1F

4 more assets in the full pipeline.

Request access →

Partnerships

Seeking global partners for development, clinical trials, and commercialization

Beyond the preview

Go deeper on Hefei TG ImmunoPharma Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hefei TG ImmunoPharma Co., Ltd..

Explore the full profile